Melsjan Shkullaku, MD
Interventional Cardiology · Annapolis, MDNPI 1316246598
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (50.8%), grants and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 76.7% of it on its own, with 27 other manufacturers making up the rest.
Across 174 payments — averaging $190.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$25K
- Edwards Lifesciences$4K
- Abiomed$756
- Butterfly Network, Inc.$565
- Boston Scientific$388
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$283
- plus $2K from 22 others
What the payments were for
- Consulting fees$5652%
- Grants$9,00027%
- Travel & lodging$16,81051%
- Food & beverage$6,69720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 70 | $25,352 |
| Edwards Lifesciences | 24 | $4,125 |
| Abiomed | 4 | $756 |
| Butterfly Network, Inc. | 1 | $565 |
| Boston Scientific | 10 | $388 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $283 |
| Abbott | 3 | $278 |
| Novartis | 8 | $165 |
| Shockwave Medical, Inc | 1 | $143 |
| Pfizer | 5 | $119 |
| Novo Nordisk | 2 | $105 |
| Silk Road Medical, Inc. | 3 | $98 |
| Johnson & Johnson | 4 | $97 |
| Amgen | 4 | $94 |
| AstraZeneca | 4 | $66 |
| Medicomp Inc | 3 | $65 |
| E.r. Squibb & Sons, L.L.C. | 4 | $63 |
| Cardiva Medical, Inc. | 2 | $55 |
| Baxter Healthcare | 1 | $53 |
| Cleerly, Inc. | 2 | $45 |
| Atricure, Inc. | 1 | $34 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| Merck | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Kestra Medical Technology Services, Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Cardinal Health 200 LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$12,160
- CoreValve Evolut$9,000
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,817
- COUGAR$1,658
- Impella$527
- Mitra Clip system$254
- SAPIEN 3 Ultra RESILIA$237
- COBALT DR MRI SURESCAN$153
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$143
- RESOLUTE ONYX$142
- SelectSecure$136
- MyCareLink$136
- ENROUTE Transcarotid Neuroprotection System$119
- AURORA EV-ICD MRI SURESCAN$101
How this compares
$33,072 in reported general payments places this provider in the 80th percentile of 71 interventional cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 118 | $94,272 |
| EntrestoSacubitril/Valsartan | 18 | $27,568 |
| XareltoRivaroxaban | 21 | $21,899 |
| Rosuvastatin Calcium | 174 | $4,545 |
| Metoprolol Succinate | 118 | $2,051 |
| ClopidogrelClopidogrel Bisulfate | 60 | $1,299 |
| Valsartan | 45 | $1,025 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 36 | $933 |
| Amiodarone Hcl | 17 | $862 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 14 | $830 |
| Atorvastatin Calcium | 36 | $498 |
| Nifedipine ErNifedipine | 18 | $377 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 21 | $364 |
| Torsemide | 18 | $309 |
| Furosemide | 80 | $287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $119 | $94,272118 claims |
| NovartisEntresto | $165 | $27,56818 claims |
| Johnson & JohnsonXarelto | $97 | $21,89921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 71 interventional cardiology providers in Maryland.
Other interventional cardiology in Annapolis
- Elizabeth ReineckAnnapolis$11K
- Vinay SatwahGreenbelt$679K
- Aloke FinnBaltimore$575K
- Michael ChenRockville$241K
- John WangBaltimore$138K
- Steven HearneSalisbury$100K
- Amir NajafiBel Air$82K
- Diljon ChahalBaltimore$78K
- Joseph CinderellaSalisbury$72K
- Ali TabrizchiBel Air$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.